Shenping Medical's LAVA Liquid Embolic System: First-in-Class Neurointerventional Device to Obtain CE Certification for Overseas Markets

Stroke is the most common cerebrovascular disease in clinical practice, characterized by high rates of disability and mortality. For many years, the treatment of stroke has remained a major challenge in neurosurgery. In recent years, with the advancement of endovascular interventional techniques, endovascular embolization therapy has been increasingly widely adopted and has become a crucial component of comprehensive cerebrovascular disease management. The LAVA Liquid Embolic System, introduced by Shenping Medical, is expected to further enhance the efficacy of embolization therapy for cerebrovascular diseases and expand its application scope, thereby offering greater benefits to more patients suffering from arteriovenous malformations (AVMs) who face pain and life-threatening risks.

Artery Select New Product Review, Issue 6, featuringProfessor Li Youxiang, Chief Physician of the Department of Neurosurgery at Beijing Tiantan Hospital, and Mr. Qiu Haiping, Founder of Shenping MedicalProduct Interpretation of the Shenping Medical LAVA Liquid Embolic System

The LAVA Liquid Embolic System is primarily composed of organic compounds and polymers. In May 2021, the LAVA Liquid Embolic System successfully obtained CE certification, becoming the first Chinese neurointerventional device of its kind to receive such approval for overseas market entry. The product has received consistent acclaim from clinicians abroad for its clinical performance. Currently, the LAVA Liquid Embolic System is expected to complete clinical trials in 2023 and obtain registration with the National Medical Products Administration (NMPA) in 2024.

Compared with similar products currently on the market, the LAVA Liquid Embolization System introduced by Shenping Medical features the following characteristics:

1. Non-adhesive material: Low injection resistance, relatively easier catheter removal, and enhanced safety;

2. Proprietary low-viscosity formula, most comprehensive range of models: LAVA-12, LAVA-18, LAVA-34;

3. Superior diffusivity and permeability: deeply penetrates lesions, reaching the distal ends of microvasculature;

4. Improved Anti-Settling and Development Properties: Finer tantalum powder results in slower sedimentation and clearer development.

To provide a more comprehensive understanding, Shenping Medical’s LAVA Liquid Embolization System will be featured in a live-streamed presentation on the “VCBeat Select New Product Showcase” from 19:30 to 20:30 on Monday, April 17, 2023.

At this event, Mr. Qiu Haiping, Founder of Shenping Medical, was invited to deliver a corporate overview, while Professor Li Youxiang, Chief Physician of the Department of Neurosurgery at Beijing Tiantan Hospital, presented the product introduction.Welcome to scan the QR code in the poster below to register for the live broadcast:

Li Youxiang

Chief Physician, Department of Neurosurgery, Beijing Tiantan Hospital

M.D., Chief Physician, Doctoral Supervisor; Chief Physician, Department of Neurosurgery, Beijing Tiantan Hospital; Director, Neurointerventional Research Laboratory, Beijing Neurosurgical Institute; Member, Interventional Group, Society of Neurological Surgery, Chinese Medical Association; Secretary-General, Academic Committee on Cerebrovascular Treatment, Chinese Medical Doctor Association; Chief Expert, Beijing Clinical Research Center for Cerebrovascular Diseases; Guiding Expert for Continuing Medical Education in Clinical Medicine, Ministry of Education. Primarily engaged in basic and clinical research on endovascular embolization for hemorrhagic cerebrovascular diseases.

Qiu Haiping

Founder of Zhuhai Shenping Medical Co., Ltd.

Investor in BLOCKADE and TRM, companies in the U.S. neurointerventional medical sector; introduced neurointerventional products from Irvine (the “Second Silicon Valley” of the U.S.) and established a technical collaboration platform; conducts in-depth research on major global neurointerventional brands and possesses extensive expertise in the clinical application of neurointerventional devices; has 23 years of experience in the medical device industry, accumulating substantial professional networks and channel resources.

Zhuhai Shenping Medical Co., Ltd. was established in August 2016 with a registered capital of RMB 49.28 million. Located at Gangwan No. 2 · Shuangbo Base in the Zhuhai High-Tech Industrial Development Zone, the company operates a manufacturing facility spanning over 2,000 square meters. As a high-tech enterprise, it focuses on providing comprehensive medical solutions for stroke. Shenping Medical is committed to delivering high-quality, integrated neurointerventional solutions for patients. Through years of technological research and development, innovation, and accumulation, the company has developed a series of Class III neurointerventional medical devices with independent intellectual property rights, which have received consistent acclaim from clinicians both domestically and internationally.

"Artery Select New Product Showcase" is a live-streaming program under "Artery Select" that supports the launch of innovative products by healthcare companies. The program's mission is to support every milestone launch of innovative medical products.

Scan the QR Code to Reserve Your Spot for the Live Stream